Literature DB >> 14632841

ErbB receptors: possible therapeutic targets in prostate cancer?

H L Ratan1, A Gescher, W P Steward, J K Mellon.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14632841     DOI： 10.1111/j.1464-410x.2003.04503.x

Source DB:  PubMed          Journal:  BJU Int        ISSN： 1464-4096            Impact factor:   5.588


× No keyword cloud information.
  9 in total

Review 1.  Molecular mechanisms involving prostate cancer racial disparity.

Authors:  Cansu Karakas; Cassie Wang; Fangming Deng; Hongying Huang; Dongwen Wang; Peng Lee
Journal:  Am J Clin Exp Urol       Date:  2017-11-09

2.  Eastern Cooperative Oncology Group Phase II Trial of lapatinib in men with biochemically relapsed, androgen dependent prostate cancer.

Authors:  Glenn Liu; Yu-Hui Chen; Jill Kolesar; Wei Huang; Robert Dipaola; Michael Pins; Michael Carducci; Mark Stein; Glenn J Bubley; George Wilding
Journal:  Urol Oncol       Date:  2011-07-23       Impact factor: 3.498

3.  Lupeol inhibits proliferation of human prostate cancer cells by targeting beta-catenin signaling.

Authors:  Mohammad Saleem; Imtiyaz Murtaza; Rohinton S Tarapore; Yewseok Suh; Vaqar Mustafa Adhami; Jeremy James Johnson; Imtiaz Ahmad Siddiqui; Naghma Khan; Mohammad Asim; Bilal Bin Hafeez; Mohammed Talha Shekhani; Benyi Li; Hasan Mukhtar
Journal:  Carcinogenesis       Date:  2009-02-20       Impact factor: 4.944

4.  Molecular mechanisms involving prostate cancer racial disparity.

Authors:  David Hatcher; Garrett Daniels; Iman Osman; Peng Lee
Journal:  Am J Transl Res       Date:  2009-04-20       Impact factor: 4.060

5.  ErbB-2 signaling plays a critical role in regulating androgen-sensitive and castration-resistant androgen receptor-positive prostate cancer cells.

Authors:  Sakthivel Muniyan; Siu-Ju Chen; Fen-Fen Lin; Zhengzhong Wang; Parmender P Mehta; Surinder K Batra; Ming-Fong Lin
Journal:  Cell Signal       Date:  2015-08-06       Impact factor: 4.315

6.  EGF prevents the neuroendocrine differentiation of LNCaP cells induced by serum deprivation: the modulator role of PI3K/Akt.

Authors:  Rosa M Martín-Orozco; Carmén Almaraz-Pro; F Javier Rodríguez-Ubreva; M Alicia Cortés; Santiago Ropero; Ramón Colomer; Pilar López-Ruiz; Begoña Colás
Journal:  Neoplasia       Date:  2007-08       Impact factor: 5.715

Review 7.  [Taxanes in the chemotherapy of hormone-refractory prostate carcinoma].

Authors:  M Johannsen; K Wilke; D Schnorr; S A Loening
Journal:  Urologe A       Date:  2004-02       Impact factor: 0.639

Review 8.  Molecular basis for prostate cancer racial disparities.

Authors:  Santosh K Singh; James W Lillard; Rajesh Singh
Journal:  Front Biosci (Landmark Ed)       Date:  2017-01-01

9.  MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer.

Authors:  Wenqing Qi; Larry S Cooke; Amy Stejskal; Christopher Riley; Kimiko Della Croce; Jose W Saldanha; David Bearss; Daruka Mahadevan
Journal:  BMC Cancer       Date:  2009-05-11       Impact factor: 4.430
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.